Combogesic® IV (acetaminophen and ibuprofen)
Approval Date: Oct 2023
Indicated for the short term management of mild to moderate acute pain, and the management of moderate to severe pain as an adjunct to opioid analgesics, this drug is now available in an intravenous formulation
Advil Dual Action (acetaminophen and ibuprofen) tablets (OTC)
Approval Date: Feb 2023
Temporarily relieves minor aches and pains due to headache, toothache, backache, menstrual cramps, muscular aches, minor pain of arthritis
Combogesic® (acetaminophen and ibuprofen) tablets
Approval Date: Mar 2023
Indicated for the short term management of mild to moderate acute pain
Nalfon® (fenoprofen calcium) tablets
Approval Date: Jul 2022
An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis
Seglentis (celecoxib and tramadol hydrochloride) tablets
Approval Date: Oct 2021
A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate
Belbuca® (buprenorphine) buccal film
Approval Date: Aug 2021
This is the first time a generic has been approved for Belbuca. For the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate
ZYNRELEF™ (BUPIVACAINE AND MELOXICAM) EXTENDED-RELEASE SOLUTION
Approval Date: May 2021
A combination of an amide local anesthetic and an NSAID for postsurgical analgesia for up to 72 hours after bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty
LYRICA® CR (PREGABALIN) EXTENDED-RELEASE TABLETS
Approval Date: Apr 2021
For the management of neuropathic pain associated with diabetic neuropathy; post-herpetic neuralgia. While previous generic versions of Lyrica have been approved in the past, this generic approval is for the Extended-Release tablets
HYSINGLA® ER (HYDROCODONE BITARTRATE) EXTENDED-RELEASE TABLETS
Approval Date: Mar 2021
For the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Posimir® (bupivacaine solution) for infiltration use
Approval Date: Feb 2021
Indicated for 72-hour post-surgical analgesia following shoulder surgery